Effects of postmenopausal hormone replacement therapy on lipoproteins including lipoprotein(a) and LDL subfractions

Atherosclerosis

Volumn 126, Issue 1, 1996, Pages 77-84

  Farish, E ^a   Spowart, K ^a   Barnes, J F ^a   Fletcher, C D ^a   Calder, A ^a   Brown, A ^a   Hart, D M ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Hormone replacement; LDL subfractions; Lipoprotein(a); Lipoproteins; Postmenopausal

Indexed keywords

CHOLESTEROL; ESTRADIOL; ESTROFEM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NORETHISTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL TRIAL; FEMALE; HORMONE SUBSTITUTION; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MENOPAUSE; PRIORITY JOURNAL;

EID: 0030604002     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05895-9     Document Type: Article

References (37)

1. [1] Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47.
2. [2] Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. J Am Med Assoc 1991;265:1861.
3. [3] Whitehead M, Lobo RA. Progestogen use in postmenopausal women. Consensus Conference. Lancet 1988;ii:1243.
4. [4] Farish E, Fletcher CD, Hart DM, Teo C, Alazzawi F, Howie C. The effects of conjugated equine oestrogens with and without a cyclical progestogen on lipoproteins and HDL subfractions in postmenopausal women. Acta Endocrinol 1986;113:123.
5. [5] Austin MA, Hokanson JE. Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. Med Clin North Am 1994;78:99.
6. [6] Cremer P, Nagel D, Labrot B, Mann H, Muche R, Elster H, Seidel D. Lipoprotein(a) as a predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). Eur J CHn Invest 1994;24:444.
7. [7] Lobo RA, Notelovitz M, Bernstein L, Khan FY, Ross RK, Paul WL. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise and estrogen. Am J Obstet Gynecol 1992;166:1182.
8. [8] Farish E, Rolton HA, Barnes JF, Fletcher CD, Walsh DJ, Spowart KJM, Hart DM. Lipoprotein(a) and postmenopausal oestrogen. Acta Endocrinol 1993;129:225.
9. [9] Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. Br Med J 1991;303:694.
10. [10] Soma MR, Osnago-Gadda I, Paoletti R, Fumagalli R, Morrisett JD, Meschia M, Croisgnani P. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993;153:1462.
11. [11] Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069.
12. [12] Muesing RA, Miller VT, Mills TL, La Rosa JC. Effects of postmenopausal unopposed estrogen and combined therapy on lipoprotein(a) levels. Arterioscl Thromb 1991;11:1452a.
13. [13] Krauss RM. Low-density lipoprotein subclasses and risk of coronary artery disease. Curr Opin Lipidol 1991;2:248.
14. [14] Roheim PS, Asztalos BF. Clinical significance of lipoprotein size and risk for coronary atherosclerosis. Clin Chem 1995;41:147.
15. [15] Campos H, Genest JJ, Blijlevens E, McNamara JR, Jenner JL. Low density lipoprotein particle size and coronary artery disease. Arterioscl Thromb 1992;12:187.
16. [16] Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990;83:59.
17. [17] Tikkanen MJ, Nikkila EA. Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J 1987;113:562.
18. [18] Watson TDG, Caslake MJ, Freeman DJ, Griffin BA, Hinnie J, Packard CJ, Shepherd J. Determinants of low density lipoprotein subfraction distribution and concentrations in young normolipidemic subjects. Arterioscl Thromb 1994;14:902.
19. [19] Patsch JR, Prasad S, Gotto AM, Patsch W. High density lipoprotein2: relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipaemia, and to the activities of lipoprotein lipase and heptic lipase. J Clin Invest 1987;80:341.
20. [20] Griffin B, Farish E, Walsh D, Barnes J, Caslake M, Shepherd J, Hart D. Response of plasma low density lipoprotein subfractions to oestrogen replacement therapy folllowing surgical menopause. Clin Endocrinol 1993;39:463.
21. [21] Fletcher CD, Barnes JF, Farish E. A rapid semi-micro method for the separation of lipoprotein fractions that uses a benchtop ultracentrifuge. Clin Chim Acta 1994;226:95.
22. [22] Labeur C, Bacquer D, De Backer G, Vincque J, Muyldermans L, Vanderckhove Y, Van der Stichele E, Rossenau M. Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem 1992;38:2261.
23. [23] Fahreus L, Wallentin L. High density lipoprotein subfractions during oral and cutaneous administration of 17-estradiol to menopausal women. J Clin Endocrinol Metab 1983;56:797.
24. [24] Farish E, Fletcher CD, Dagen MM, Hart DM, Alazzawi F, Parkin DE, Howie CA. Lipoprotein and apoprotein levels in postmenopausal women on continuous oestrogen/progestogen therapy. Br J Obstet Gynecol 1989;96:358.
25. [25] Sporrong T, Hellgren M, Samsoie G, Mattson L-A. Metabolic effects of continuous estradiol-progestin therapy in postmenopausal women. Obstet Gynecol 1989;73:745.
26. [26] Rymer J, Crook D, Sidhu H, Chapman M, Stevenson JC. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol 1993;128:259.
27. [27] Farish E, Barnes JF, Rolton HA, Spowart K, Fletcher CD, Hart DM. Effects of tibolone on lipoprotein(a) and HDL subfractions. Maturitas 1995;20:215.
28. [28] Mackness MI, Bhatnager D, Weiringa G, MBewu A, Haynes B, Durrington PN. A comparative study of six commercial lipoprotein(a) assays in seventeen laboratories within the British Isles. Ann Clin Boichem 1996;33:63.
29. [29] de Graaf J, Swinkels DW, Demacker P, de Haan AFJ, Stalenhoef AFH. Difference in the low density lipoprotein subfraction profile between oral contraceptive users and controls. J Clin Endocrinol Metab 1993;76:197.
30. [30] Granfone A, Campos H, McNamara JR, Schaffer MM, Lamon-Fava S, Ordovas JM, Schaefer EJ. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in post menopausal dyslipidaemic women. Metabolism 1992;41:1193.
31. [31] Campos H, Sacks FM, Walsh BW, Schiff I, O'Hanesian MA, Krauss RM. Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women. Metabolism 1993;42:1153.
32. [32] van der Mooren MJ, de Graaf J, Demacker PNM, de Haan AFJ, Rolland R. Changes in the low-density lipoprotein profile during 17B-estradiol-dydrogesterone therapy in postmenopausal women. Metabolism 1994;43:799.
33. [33] Farish E, Fletcher CD, Hart DM, Kitchener H, Sharpe GLM. A long term study of the effects of norethisterone on lipoprotein metabolism in menopausal women. Clin Chim Acta 1983;132:193.
34. [34] McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age and lipid status on low density lipoprotein subfraction distribution. Arterioscl Thromb 1987;7:483.
35. [35] Swinkels DW, Demacker PNM, Hendricks JCM, van't Laar A. Low density lipoprotein subfractions and relationship to other risk factors for coronary artery disease in healthy individuals. Arterioscl Thromb 1989;9:604.
36. [36] Williams PT, Vranizan KM, Krauss RM. Correlations of plasma lipoproteins with LDL subfractions by particle size in men and women. J Lipid Res 1992;33:765.
37. [37] Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992;95:69.